Inborn metabolic errors are a diverse range of illnesses that can be inherited or result from natural mutation. Non-fulfillment of metabolic processes involved in the breakdown or storage of carbohydrates, fatty acids, or proteins causes several illnesses. Inborn errors of metabolism (IEM) are hereditary illnesses caused by mutations in genes that code for metabolism-related proteins. In one out of every 2000 newborns, a metabolic mistake is present. Carbohydrate metabolism, protein metabolism, fatty acid oxidation, and glycogen storage are all disrupted by IEM. Dietary nutrients are broken down in the body into glucose (the body's principal energy source) and other metabolic products, which are then eliminated. Patients with numerous glucose metabolism abnormalities present early in life (usually in the neonatal period). They might present with symptoms similar to Hypoglycemia, brady and tachycardias, hypothermia or hyperpyrexia, seizures, and hypotonia are several symptoms that septic newborns can have. In an emergency, a final diagnosis of inborn metabolic abnormalities is not a reasonable aim. However, because lab abnormalities in these patients may be transient, more blood should be drawn for further testing while they are still in the early stages. The PALS/ACLS method is used to administer vigorous resuscitation to these individuals. If you suspect a patient has inborn mistakes, don't give them anything by mouth (NBM). Because the emergency physician has no way of knowing which section of the metabolic pathway is malfunctioning, it's best to keep the patient from using his or her natural pathways for carbohydrate metabolism, metabolite clearance, or accessing nutrients of stored energy. It is therefore important for primary care providers to know how to recognize those conditions, manage them in the temporary while awaiting definitive diagnosis and refer them to the appropriate higher center for collaborative management of these patients.
Stenton SL, Kremer LS, Kopajtich R, Ludwig C, Prokisch H. The diagnosis of inborn errors of metabolism by an integrative “multi?omics” approach: A perspective encompassing genomics, transcriptomics, and proteomics. Journal of inherited metabolic disease. 2020 Jan;43(1):25-35.
Marques EP, Wyse AT. Creatine as a neuroprotector: an actor that can play many parts. Neurotoxicity Research. 2019 Aug;36(2):411-23.
Guerrero RB, Kloke KM, Salazar D. Inborn Errors of Metabolism and the Gastrointestinal Tract. Gastroenterology Clinics. 2019 Jun 1;48(2):183-98.
Canton M, Le Gall D, Feillet F, Bonnemains C, Roy A. Neuropsychological profile of children with early and continuously treated phenylketonuria: systematic review and future approaches. Journal of the International Neuropsychological Society. 2019 Jul;25(6):624-43.
Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000;105 (1):e10.
Ferreira CR, Cassiman D, Blau N. Clinical and biochemical footprints of inherited metabolic diseases. II. Metabolic liver diseases. Molecular Genetics and Metabolism. 2019 Jun 1;127(2):117-21.
Huang D, Zhou Q, Chao YQ, Zou CC. Clinical features and genetic analysis of childhood sitosterolemia: Two case reports and literature review. Medicine. 2019 Apr;98(15).
Saudubray JM, Garcia-Cazorla A. An overview of inborn errors of metabolism affecting the brain: from neurodevelopment to neurodegenerative disorders. Dialogues in clinical neuroscience. 2022 Apr 1.
Rutten MG, Rots MG, Oosterveer MH. Exploiting epigenetics for the treatment of inborn errors of metabolism. Journal of inherited metabolic disease. 2020 Jan;43(1):63-70.
Ferreira CR, Hoffmann GF, Blau N. Clinical and biochemical footprints of inherited metabolic diseases. I. Movement disorders. Molecular Genetics and Metabolism. 2019 May 1;127(1):28-30.
Eanmonod R, Asuka E, Jeanmonod D. Inborn Errors Of Metabolism. [Updated 2021 Nov 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459183/
Pearson TS, Pons R, Ghaoui R, Sue CM. Genetic mimics of cerebral palsy. Movement disorders. 2019 May;34(5):625-36.
Williams C, van der Meij BS, Nisbet J, Mcgill J, Wilkinson SA. Nutrition process improvements for adult inpatients with inborn errors of metabolism using the i?PARIHS framework. Nutrition & Dietetics. 2019 Apr;76(2):141-9.
Zschocke J, Hoffmann GF. Vademecum Metabolicum: Diagnosis and Treatment of Inborn Errors of Metabolism. 3rd ed. http://evm. health2media.com/#/detail-view/about/0/0. Accessed August 31, 2018.
Klouwer FC, Berendse K, Ferdinandusse S, et al. Zellweger spectrum disorders. Orphanet J Rare Dis. 2015;10:151.
Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmoglobulinemia D syndrome. Orphanet J Rare Dis. 2006;1:13.
Freeze HH, Eklund EA, Ng BG, Patterson MC. Neurology of inherited glycosylation disorders. Lancet Neurol. 2012;11(5):453-466.
Campos D, Monaga M. Mucopolysaccharidosis type I. Metab Brain Dis. 2012;27(2):121-129.
Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2):e377-e386.
Pastores GM, Hughes DA. Gaucher Disease. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; July 27, 2000 [updated June 21, 2018]:1993-2018.
Vallance H, Ford J. Carrier testing for autosomal-recessive disorders. Crit Rev Clin Lab Sci. 2003;40(4):473-497.
Kaback M, Lim-Steele J, Dabholkar D, et al. Tay-Sachs disease—carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. JAMA. 1993;270(19):2307-2315.
Committee on Genetics. Committee Opinion No. 691: carrier screening for genetic conditions. Obstet Gynecol. 2017;129(3):e41-e55.
Gross SJ, Pletcher BA, Monaghan KG; Professional Practice and Guidelines Committee. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008;10(1):54-56.
Edwards JG, Feldman G, Goldberg J, et al. Expanded carrier screening in reproductive medicine-points to consider. Obstet Gynecol. 2015; 125(3):653-662.
Lund AM, Hougaard DM, Simonsen H, et al. Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland. Mol Genet Metab. 2012;107(3):281-293.
Vilarinho L, Rocha H, Sousa C, et al. Four years of expanded newborn screening in Portugal with tandem mass spectrometry. J Inherit Metab Dis. 2010;33(suppl 3):S133-S138.
Schiff M, Mochel F, Dionisi-Vici C. Emergency Treatments. In: Inborn Metabolic Diseases. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016:109-17.
Agana M, Frueh J, Kamboj M, Patel DR, Kanungo S. Common metabolic disorder (inborn errors of metabolism) concerns in primary care practice. Ann Transl Med. 2018 Dec;6(24):469. doi: 10.21037/atm.2018.12.34. PMID: 30740400; PMCID: PMC6331353.
Van Karnebeek CDM, Bowden K, Berry-Kravis E. Treatment of Neurogenetic Developmental Conditions: From 2016 into the Future. Pediatr Neurol 2016;65:1-13. 10.1016/j.pediatrneurol.2016.07.010
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright (c) 2023 Dr. Naveen Reddy, Dr. Abhijit Shinde, Dr. Sunil Natha Mhaske, Dr. Suresh Waydande, Dr. Harish Jadhav